SenesTech Receives Nasdaq Noncompliance Letter; Preliminary Q3 Revenue ~$1.1M

SenesTech, Inc. (NASDAQ:SNES), the leader in rodent birth control and sustainable rodent population management, today announced that, on Oct. 20, 2026, it received a letter from the listing qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the closing bid price of its common stock had been below $1.00 per share for 30 consecutive business days. As a result, the Company does not currently meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

The notification has no immediate effect on the listing of SenesTech’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "SNES." Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 19, 2027, to regain compliance.

"We take the Nasdaq notification seriously, and we intend to use the compliance period to keep demonstrating the progress we are making in the business," said Michael Edell, President and Chief Executive Officer of SenesTech. "Our preliminary third quarter revenue of approximately $1.1 million was the highest in the Company’s history, up 40% from the second quarter and 55% from the third quarter of 2025. We believe that continued execution, together with broader investor awareness of our progress, can create opportunities for our share price to better reflect the value we see in the business."

Recently, long term holder Glenbrook Capital Management congratulated SenesTech on its recently announced 40% sequential and 55% year-over-year revenue growth in Q3. It has also reported a 38% ownership position and offered to work cooperatively with the Board and management team on practical measures designed to improve the Company's financial position and support operating priorities.

SenesTech intends to take a disciplined approach to financial management, balancing the need to maintain adequate liquidity and financial resources against the cost of capital and dilution to existing shareholders. The Company continues to evaluate its financing requirements and available alternatives, as well as the other options available to it to regain compliance with the Nasdaq listing rules.